Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine  

One consistently identified abnormality in autism is a reduction in one of the receptors (nicotinic) for the neurotransmitter acetylcholine. The proposed pilot trial aims to test the response of individuals with autism to agents that target this receptor type, thus changing acetylcholine signaling. There is one nicotinic agent that has been shown to be safe in other childhood-onset disorders. This agent will be pilot-tested in children with autism. Twenty children with autism spectrum disorder will receive the drug or placebo over 13 weeks in a controlled (placebo double-blind) trial. The outcome will be assessed by standard clinical rating scales which will measure a range of behavioral and communicative functions, including attention. Computerized testing will also be used to assess changes in attention objectively. Project Status
ONGOING

2010

Funder Autism Speaks
Fiscal Year Funding $0.00
Current Award Period 2007-2010
Project Number 2368
Principal Investigator Arnold, L. Eugene
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Treatments)
Subcategory Medical/Pharmacologic
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4LA. Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014. IACC Recommended Budget: $22,200,000 over 5 years.
Federal or Private? Private
Institution The Ohio State University
State/Country Ohio
Web Link 1 Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects Neuronal nicotinic receptor modulation in the treatment of autism: A pilot trial of mecamylamine | $44,916.55 | 2009 | 2368